Evidence map›Paper›PMID 35773092›Full record

ArticleEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology2022

Surgery in combination with systemic chemotherapy is associated with improved survival in stage IV gallbladder cancer.

Anthony S Casabianca, Vasileios Tsagkalidis, Paul R Burchard, Alexander Chacon, Alexa Melucci, Alexandra Reitz, David A Swift, Ashley A McCook, Jeffrey M Switchenko, Mihir M Shah and 1 more

Open access · greenAbstract read
In one paragraph

Article in European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Anthony S CasabiancaDepartment of Surgery, Division of General Surgery, University of Rochester, Rochester, NY, USA.
Vasileios TsagkalidisDepartment of Surgery, Division of General Surgery, University of Rochester, Rochester, NY, USA.
Paul R BurchardDepartment of Surgery, Division of General Surgery, University of Rochester, Rochester, NY, USA.
Alexander ChaconDepartment of Surgery, Division of General Surgery, University of Rochester, Rochester, NY, USA.
Alexa MelucciDepartment of Surgery, Division of General Surgery, University of Rochester, Rochester, NY, USA.
Alexandra ReitzDepartment of General Surgery, Emory University School of Medicine, Atlanta, GA, USA.
David A SwiftDepartment of General Surgery, Emory University School of Medicine, Atlanta, GA, USA.
Ashley A McCookDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Jeffrey M SwitchenkoDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Mihir M ShahDepartment of Surgery, Division of Surgical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Darren R CarpizoDepartment of Surgery, Division of Surgical Oncology, University of Rochester, NY, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: darren_carpizo@urmc.rochester.edu.
Emory University · USUniversity of Rochester · USUniversity of Rochester Medical Center · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancerDrugsR01CA200800 · NCI · UNIVERSITY OF ROCHESTER · PI CARPIZO, DARREN RICHARD · 2016 to 2020
$1.9M
NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA200800
6 · The paper itself

Abstract

backgroundGallbladder cancer (GBC) is the most common biliary malignancy frequently metastatic at diagnosis with poor prognosis. While surgery remains the standard for early-stage GBC, the role of surgery in patients with metastatic gastrointestinal cancers is expanding due to improvements in systemic therapies. We sought to evaluate the survival of patients with stage IV GBC undergoing surgery in an era of improved multi-agent systemic therapy.

methodsA retrospective review of the National Cancer Database was performed. Patients with stage IV GBC who underwent systemic therapy were included. Patients who received radiation therapy, palliative therapy or had missing survival data were excluded. Univariable and multivariable analysis was performed.

results4,145 patients were identified between 2004 and 2016. Mean age was 69. Surgery combined with systemic therapy predicted improved median survival compared with chemotherapy alone (11.1mo versus 6.8mo, HR 0.65, p < 0.001). Additionally, receipt of treatment after 2011 predicted improved survival (HR 0.86, p < 0.001). Patients treated with multi-agent chemotherapy in combination with surgery were associated with the greatest hazard ratio benefit (0.40, p < 0.001) versus single agent therapy alone.

conclusionPatients with stage IV gallbladder cancer treated with a combination of surgery and chemotherapy are associated with an improved overall survival compared to chemotherapy alone. Patients receiving care during the more recent era demonstrated improved survival. These results support a role for surgery in selected patients with stage IV gallbladder cancer receiving chemotherapy.

Indexed as

Gallbladder NeoplasmsAgedHumansNeoplasm StagingProportional Hazards ModelsRetrospective Studies

Identifiers

PMID35773092
PMCPMC10993821
OpenAlexW4283265839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.